F01 in the Treatment of Relapsed/Refractory Non-hodgkin ' s Lymphoma
Conditions: Non-Hodgkin ' s Lymphoma Interventions: Drug: After preconditioning with chemotherapy, F01 will be evaluated. Sponsors: Shanghai Simnova Biotechnology Co.,Ltd.; Wuhan Union Hospital, China Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Chemotherapy | China Health | COVID-19 | Hospitals | Lymphoma | Non-Hodgkin's Lymphoma | Research